Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

about

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Item

http://www.wikidata.org/entity/Q50189731

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Defibrotide sodium for the tre ...... nusoidal obstruction syndrome.

@en

Defibrotide sodium for the tre ...... nusoidal obstruction syndrome.

@nl

type

Item

label

Defibrotide sodium for the tre ...... nusoidal obstruction syndrome.

@en

Defibrotide sodium for the tre ...... nusoidal obstruction syndrome.

@nl

prefLabel

Defibrotide sodium for the tre ...... nusoidal obstruction syndrome.

@en

Defibrotide sodium for the tre ...... nusoidal obstruction syndrome.

@nl

P1476

Defibrotide sodium for the tre ...... inusoidal obstruction syndrome

@en

P2093

Fiona L Dignan

http://www.w3.org/2001/XMLSchema#string

Michelle Maglio

http://www.w3.org/2001/XMLSchema#string

Mohamad Mohty

http://www.w3.org/2001/XMLSchema#string

Nelson Chao

http://www.w3.org/2001/XMLSchema#string

Paul G Richardson

http://www.w3.org/2001/XMLSchema#string

Vincent T Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.

Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation--role of transjugular intrahepatic portosystemic shunt (TIPS).

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.

Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria

Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation.

P304

113-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2018.1421943

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Brandon M Triplett

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29301447

http://www.w3.org/2001/XMLSchema#string